The test detects genomic drug resistance mutations in HIV-1 that can lead to treatment failure and is validated on the firm's automated Sentosa workflow.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
The assay's CE marking permits its use for the early diagnosis of HIV-1 in infants and for measuring viral load and disease progression using dried blood spot samples.
The assay, which uses the Bioneer ExiStation molecular diagnostics instrument, was also recently registered for purchase by the Global Fund.
The partners are planning to integrate the technology into Horizon's research tools and services and to develop it for applications in cell therapeutics.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
As they dig into the data on He Jiankui's genome editing experiment, CRISPR researchers say the work he did raises many scientific questions.
Even as He Jiankui expressed pride in the work he had done to alter the CCR5 genes of twin embryos, researchers and ethicists decried him as misguided.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.